tbuckley/cabot-search huggingface dataset:
Molecular Prediction of Recurrence of Breast Cancer
Authors: James F Lombardo
Journal: New England Journal of Medicine (2005)

1300 n engl j med 353;12 www.nejm.org september 22, 2005 cancers detected today, our results present a difficulty in clinical decision making, as we pointed out in our paper. However, it is certain that even if a better relative risk reduction than reported in our study can be achieved, the resulting absolute reduction in a group that enjoys a very good prognosis at the outset will be moderate or small. Anna Bill-Axelson, M.D., Ph.D. Lars Holmberg, M.D., Ph.D.
Sexual behaviours, HIV testing, and the proportion of men at risk of transmitting and acquiring HIV in London, UK, 2000–13: a serial cross-sectional study
Authors: Adamma Aghaizu, Sonali Wayal, Anthony Nardone, Victoria Parsons, Andrew Copas, Danielle Mercey, Graham Hart, Richard Gilson, Anne M Johnson
Journal: The Lancet HIV (2016)
Abstract 147: δ-opioid Receptor Activation Increases Nrf2 Nuclear Translocation And Stabilizes Mitochondrial Membrane Potential Of Hypoxic Cells
Authors: Shan Cao, Tao Chen, Dongman Chao, Guoqiang Wen, Gianfranco Balboni, Ying Xia
Journal: Circulation Research (2014)

Conditions that limit O2 supply for a prolonged period lead to cardiac injury. However, current strategies against hypoxic cardiac injury are limited in clinical settings. It is of utmost importance to find novel clues for protecting cells from hypoxic injury. Our work has recently shown that δ-opioid receptor (DOR) activation strongly regulates microRNA expression in the heart exposed to prolonged hypoxia, suggesting a role of DOR in cardiac adaptation to hypoxic stress. To further determine DOR's action on cell survival under hypoxia and the underlying mechanisms, we exposed HEK293t cells to hypoxia for a prolonged period and then investigated cellular viability and changes in mitochondrial membrane potential and the nuclear factor erythroid 2-related factor 2 (Nrf2), which are thought to be involved in the regulation of cell survival under hypoxia. Our data show that prolonged hypoxia (0.5% of O2 for 16-48 hours) caused serious cellular injury. DOR activation with UFP-512, a potent and specific DOR agonist, prevented the collapse of mitochondrial membrane potential and markedly attenuated cell injury in the hypoxic condition. The DOR-mediated protection was largely reversed by DOR antagonism with naltrindole. Furthermore, we observed that DOR activation increased Nrf2 translocation from cytoplasm to nucleus. The DOR-mediated cytoprotection was largely abolished by the "knock-down" of Nrf2. Our results suggest that DOR activation increases Nrf2 nuclear translocation and stabilizes mitochondrial membrane potential during the process of cellular protection against hypoxic stress. SC and TC are equal contributors. Supported by HD-034852, AT-004422, NSFC 81060096 and 81260204.
A Serologic Study of the Microsome Fraction of Normal and Neoplastic Mouse Tissues
Authors: R. A. Malmgren, B. E. Bennison, B. F. Anderson, C. C. Risley
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article A Serologic Study of the Microsome Fraction of Normal and Neoplastic Mouse Tissues Get access R. A. Malmgren, R. A. Malmgren Search for other works by this author on: Oxford Academic PubMed Google Scholar B. E. Bennison, B. E. Bennison Search for other works by this author on: Oxford Academic PubMed Google Scholar B. F. Anderson, B. F. Anderson Search for other works by this author on: Oxford Academic PubMed Google Scholar C. C. Risley C. C. Risley National Cancer Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 6, June 1951, Pages 1277–1286, https://doi.org/10.1093/jnci/11.6.1277 Published: 01 June 1951 Article history Received: 17 March 1951 Published: 01 June 1951
18F-FDG PET Detection of a Medullary Thyroid Carcinoma in a Patient With SMZL
Authors: Anna Paschali, Mufaddal Moonim, Johnathan Hubbard, Hosahalli Mohan
Journal: Clinical Nuclear Medicine (2016)

Incidental thyroid FDG uptake is not rarely encountered on PET studies. In this case, we present an incidental thyroid focus of 18F-FDG uptake identified in a patient with splenic marginal zone lymphoma during the baseline and the response assessment PET/CT study that proved to be medullary thyroid carcinoma on subsequent histological examination.
Patient focused registries can improve health, care, and science
Authors: Eugene C Nelson, Mary Dixon-Woods, Paul B Batalden, Karen Homa, Aricca D Van Citters, Tamara S Morgan, Elena Eftimovska, Elliott S Fisher, John Ovretveit, Wade Harrison, Cristin Lind, Staffan Lindblad
Journal: BMJ (2016)

Large scale collection and analysis of data on patients' experiences and outcomes have become staples of successful health systems worldwide.The systems go by various names-including registries, quality registries, clinical databases, clinical audits, and quality improvement programmes 1 2 -but all collect standardised information on patients' diagnoses, care processes, and outcomes, enabling systematic comparison and analysis across multiple sites.Hundreds of what we will term, for simplicity, "registries," now exist around the world.The United Kingdom is home to over 50 clinical audit programmes, 3 the United States has over 110 federally qualified registries certified to report quality metrics, 4 and Sweden, perhaps the registry epicentre, has over 100, covering conditions from birth to frail old age. 5ese registries have had far reaching effects.They facilitate public reporting, retrospective and prospective research, professional development, and service improvement.They reveal variations in practices, processes, and outcomes, and identify targets for improvement.In the UK, they have been associated with many notable successes, including improvements in management of cardiovascular disease and stroke, 6 7 cancer, 8 and joint replacement.
Vitamin D levels in patients with childhood cancer.
Authors: Nurdan Tacyildiz, Gulsah oktay Tanyildiz, Deniz Tekin, Can Ates, Handan Dincaslan, Gulsan Yavuz, Emel Unal, Kenan Kose, Derya Ozyoruk, Emine Suskan, Omer Kucuk
Journal: Journal of Clinical Oncology (2012)

e20000 Background: There is increasing interest in the possible association between cancer incidence and vitamin D through its role as a regulator of cell growth and differentiation. Although there are several studies related cancer risk and prognosis of cancer, related vit D levels in adult patients there are only few recent studies in pediatric patients. Methods: Between 2010 and 2011, D Vit levels of 45 patients (25 boys, 20 girls; age range: 6 months-17 years, median: 11 years) have been compared to D Vit levels of 22 healthy children with similar age group. Patient groups were leukemias, lymphomas, bone tumors, retinoblastoma (RB), and other tumors. Kruskal-Wallis and Spearman nonparametric correlations test of SPSS has been used for statistics. Results: Although there was no statistically significant difference for vit D levels between control group (range: 7.2-22.8; median: 14.75 ng/ml) and patients (range: 5.5-40.2; median: 16.0 ng/ml),difference between patients groups were significant (Table). Patients with RB have statistically lower level of Vit D than leukemia (p:0.016) and lymphoma groups ( p: 0.047). “Other tumors group” has lower vit D levels than leukemia group (p: 0.024). Since RB and other tumors group have younger age than other patients, Spearsman’s nonparametric correlation has been performed to exclude age effect on the results and no statistically significant correlation between D vit levels and age (p: 0.779) was found, although there was an inverse correlation between age and vit D levels in patient group (p: 0.03). Conclusions: According to our preliminary results, most of the patients and healthy children have low level of Vit D. Especially patients with RB have statistically significant lower level of Vit D than other malignancies which can be subject to future studies for confirmation of our results. In addition, etiologic studies related RB may have a new area. [Table: see text]
Cautionary tale of active surveillance in intermediate-risk patients: Overall and cause-specific survival in the Sunnybrook experience.
Authors: Hima Bindu Musunuru, Laurence Klotz, Danny Vespirini, Liying Zhang, Alexandre Mamedov, Perakaa Sethukavalan, Vibhuti Jethava, Toshihiro Yamamoto, Suneil Jain, D. Andrew Loblaw
Journal: Journal of Clinical Oncology (2015)

163 Background: To document the long-term outcomes of intermediate risk (IR) prostate cancer patients managed on active surveillance (AS) protocol in a single institute. Methods: Patients(pts) with PSA &gt;10ng/ml or Gleason score 7 or clinical stage T2b/2c were identified from a prospectively collected database of 945 patients managed on AS between 1995 and 2013. Intervention was offered to those pts with a PSA doubling time of &lt; 3 years, Gleason score or clinical progression.Overall survival (OS), cause-specific survival (CSS) for IR and low risk (LR) pts were analyzed as well as metastasis free survival (MFS) and treatment-free survival (TFS) for IR pts. Results: 237 (23.9%) pts had IR disease, with a median follow up of 6.9 years (IQR 3.89, 10.85) .708 pts had LR cancer with a median follow up of 6.4 years (IQR 3.76, 9.03). 61.2% of the IR cohort was older than 70 years. 86 IR pts (36.3%) received treatment (mainly radiation). The median treatment free interval for IR pts was 12.3 years (range 10.1 - 19.8). 33 IR patients developed biochemical failure and 17 developed metastatic disease [11 IR pts(4.6%) and 6 LR pts(0.8%)].The 10 and 15year OS was 68.4% and 50.3% for IR pts;83.6% and 68.8% for LR pts (p value &lt;0.0001).Similarly 10 and 15 year CSS was 95.5% and 88.5% for IR ; 98.2% and 96.3% for LR pts (p value=0.006).The hazard ratio for IR pts versus LR pts was 2.08 for OS and 3.75 for CSS.IR pts had 3.75 times higher chance of dying from prostate cancer when compared to LR pts (Table). 10 year MFS and TFS were 92.1% (87.4-97.1%) and 58.5% (51.6-66.4%) in the IR cohort. Survival outcomes did not vary according to the year of patient enrollment. Conclusions: AS for intermediate risk prostate has significantly lower OS and CSS compared to low risk patients and therefore extreme caution should be exercised if it were to be implemented in intermediate risk patients. [Table: see text]
Abstract 4702: Neurological Complications After Off-pump Coronary Artery Bypass Surgery With and Without Aortic Manipulation: Meta-analysis of 11,398 Cases From 8 Studies
Authors: Martin Misfeld, R John L Brereton, Elizabeth A Sweetman, Gordon S Doig
Journal: Circulation (2009)

Background: Neurological complications following coronary artery bypass grafting remains to be of concern. Off-pump coronary artery bypass grafting (OPCAB) is one surgical strategy to decrease this risk. Use of an OPCAB “anaortic” technique, which leaves the ascending aorta untouched, may result in further reductions. This systematic review of all published evidence compares neurological complications following “anaortic” OPCAB versus OPCAB with aortic manipulation.  Methods and Results: PubMed and Embase were searched up to August 2008. Experts were contacted and reference lists of retrieved papers where hand searched. The search process was not limited to the English language. Observational studies comparing an OPCAB technique to an OPCAB “anaortic” technique were eligible for inclusion, if they reported neurological complications (stroke and transient ischemic attack). Meta-analysis was conducted to assess differences between groups with regard to neurological complications. The electronic search identified 1,428 abstracts, which resulted in the retrieval and detailed review of 331 full text papers. Eight observational studies reported neurological complications in 5,619 “anaortic” OPCAB patients and 5,779 OPCAB patients with aortic manipulation. Although patients selected for “anaortic” OPCAB tended to have a higher baseline risk of neurological complications, post-surgery neurological complications were significantly lower in these patients (odds ratio, 0.46; 95% confidence intervals, 0.29 to 0.72, I2=0.8%, p=0.0008).  Conclusions: Avoidance of aortic manipulation during OPCAB decreases neurological complications compared to OPCAB where the ascending aorta is manipulated. In patients at high-risk for stroke and/or transient ischemic attack, we recommend avoidance of aortic manipulation during OPCAB.
Inter-individual variability and genetic influences on cytokine responses to bacteria and fungi
Authors: Yang Li, Marije Oosting, Patrick Deelen, Isis Ricaño-Ponce, Sanne Smeekens, Martin Jaeger, Vasiliki Matzaraki, Morris A Swertz, Ramnik J Xavier, Lude Franke, Cisca Wijmenga, Leo A B Joosten, Vinod Kumar, Mihai G Netea
Journal: Nature Medicine (2016)
Prognostic Significance of Quantitative t(14;18) PCR Monitoring in Advanced Stage Follicular Lymphoma Patients.
Authors: Carsten Hirt, Frank Schueler, Thomas Kiefer, Antje Haas, Dietger Niederwieser, Sabine Neser, Michael Assmann, Klaus Dachselt, Malte Leithaeuser, Charles S. Rabkin, Michael Herold, Gottfried Dolken
Journal: Blood (2006)
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells
Authors: E Calura, S Pizzini, A Bisognin, A Coppe, G Sales, E Gaffo, T Fanelli, C Mannarelli, R Zini, R Norfo, V Pennucci, R Manfredini, C Romualdi, P Guglielmelli, A M Vannucchi, S Bortoluzzi
Journal: Blood Cancer Journal (2016)

Abstract microRNAs (miRNAs) are relevant in the pathogenesis of primary myelofibrosis (PMF) but our understanding is limited to specific target genes and the overall systemic scenario islacking. By both knowledge-based and ab initio approaches for comparative analysis of CD34+ cells of PMF patients and healthy controls, we identified the deregulated pathways involving miRNAs and genes and new transcriptional and post-transcriptional regulatory circuits in PMF cells. These converge in a unique and integrated cellular process, in which the role of specific miRNAs is to wire, co-regulate and allow a fine crosstalk between the involved processes. The PMF pathway includes Akt signaling, linked to Rho GTPases, CDC42, PLD2, PTEN crosstalk with the hypoxia response and Calcium-linked cellular processes connected to cyclic AMP signaling. Nested on the depicted transcriptional scenario, predicted circuits are reported, opening new hypotheses. Links between miRNAs (miR-106a-5p, miR-20b-5p, miR-20a-5p, miR-17-5p, miR-19b-3p and let-7d-5p) and key transcription factors (MYCN, ATF, CEBPA, REL, IRF and FOXJ2) and their common target genes tantalizingly suggest new path to approach the disease. The study provides a global overview of transcriptional and post-transcriptional deregulations in PMF, and, unifying consolidated and predicted data, could be helpful to identify new combinatorial therapeutic strategy. Interactive PMF network model: http://compgen.bio.unipd.it/pmf-net/ .
Implementation of a precision cancer program in an integrated health care system.
Authors: Lincoln Nadauld, Derrick S. Haslem, Gary Stone, Pravin J. Mishra, Sharanya Raghunath, Jason L. Gillman, David L. Loughmiller, James M. Ford
Journal: Journal of Clinical Oncology (2015)

e17647 Background: The advent of Next-Generation Sequencing (NGS), and other diagnostic technologies, has enabled the use of genomic information to guide targeted treatment in cancer patients. Barriers to implementation of a precision cancer clinic in a community setting include ability to perform appropriate NGS testing, interpretation of results, and drug procurement. Leveraging the advantages of an integrated healthcare delivery system, we implemented a precision cancer program for advanced cancer patients in a community setting. This program includes NGS testing, interpretation by a multi-institutional Molecular Tumor Board (MTB) and a drug navigation process. Methods: In July 2013, we began seeing metastatic cancer patients who had failed standard treatments in our precision cancer clinic. Patients with a good performance status and ability to consent were eligible. NGS was performed on fresh or archival tissue and each case was presented at our MTB which consists of experts in oncology and cancer genomics. Recommendations from the MTB were given to the treating physician, who then discussed with the patient. If it was decided to treat with the new agent, a drug navigation specialist worked with payers to obtain the drug, sometimes resulting in a complex appeals process. Patients were monitored for survival outcomes, cost and adverse events. Results: To date, 243 patients with a variety of tumor types have had NGS performed on their tumor as part of our precision cancer clinic. 188 patients (77%) had actionable mutations. This resulted in a treatment change to the targeted drug in 117 patients (62%). In addition, 38 patients (20%) have targeted options available, but are awaiting disease progression through their current treatment. Our drug navigation system has successfully obtained drug for 155 patients (82%) through insurance approval, appeals processes or clinical trials. Conclusions: Although barriers to precision cancer clinics exist, they can be overcome in the community setting through appropriate implementation of NGS, access to a MTB and a drug procurement process. In the era of personalized medicine, this model offers improved access to genomic medicine for advanced cancer patients outside of the academic setting.
A Case Report.
Authors: MICHAEL J. GARRETT
Journal: British Journal of Dermatology (1959)

Journal Article A Case Report. Get access MICHAEL J. GARRETT, M.B., F.F.R., D.M.R.T. MICHAEL J. GARRETT, M.B., F.F.R., D.M.R.T. Radium Institute, Liverpool Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 71, Issue 5, 1 May 1959, Pages 193–196, https://doi.org/10.1111/j.1365-2133.1959.tb13405.x Published: 01 May 1959
The Effect of Ectopic Autologous Grafts of Androgen-Stimulated Prostate upon the Serum “Acid” Phosphatase of the Dog
Authors: Roy Hertz, Benton B. Westfall, Morris K. Barrett, William W. Tullner
Journal: JNCI Journal of the National Cancer Institute (1949)

The Effect of Ectopic Autologous Grafts of Androgen-Stimulated Prostate upon the Serum “Acid” Phosphatase of the Dog Get access Roy Hertz, Roy Hertz National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Benton B. Westfall, Benton B. Westfall National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Morris K. Barrett, Morris K. Barrett National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar William W. Tullner William W. Tullner National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 1, August 1949, Pages 61–66, https://doi.org/10.1093/jnci/10.1.61 Published: 01 August 1949 Article history Received: 10 December 1948 Published: 01 August 1949
Review of Gaymon Bennett,<i>Technicians of Human Dignity: Bodies, Souls, and the Making of Intrinsic Worth</i><sup>1</sup>
Authors: Meaghan O'Keefe
Journal: The American Journal of Bioethics (2016)

"Review of Gaymon Bennett, Technicians of Human Dignity: Bodies, Souls, and the Making of Intrinsic Worth1." The American Journal of Bioethics, 16(8), pp. W1–W2
Novel Flow Cytometry-Based Method Of Affinity Proteomics Revealing Expression, Post-Translational Modification and Proteolysis In Primary Childhood Acute Leukemias
Authors: Veronika Kanderova, Daniela Kuzilkova, Jan Stuchly, Weiwei Wu, Anders Holm, Heidi Slåstad, Karel Fiser, Ondrej Hrusak, Fridtjof Lund-Johansen, Tomas Kalina
Journal: Blood (2013)
P-139 Monitoring of erlotinib plasma concentrations after long time administration of 100 mg in advanced pancreatic cancer patients
Authors: A. Sahmanovic, P. Buchner, M. Lichtneckert, C. Dittrich, A. Farkouh, A. Gruber, N. Baroian, M. Kitzmueller, M. Czejka
Journal: Annals of Oncology (2016)
TLR7 Ligand Potentiates GM-CSF-Initiated Antitumor Immunity Through Activation Of Plasmacytoid Dendritic Cells
Authors: Megumi Narusawa, Hiroyuki Inoue, Chika Sakamoto, Yumiko Matsumura, Atsushi Takahashi, Ayumi Watanabe, Tomoko Inoue, Shohei Miyamoto, Koichi Takayama, Makoto Inoue, Mamoru Hasegawa, Yoichi Nakanishi, Kenzaburo Tani
Journal: Blood (2013)
Tyrosine receptor kinase B is a drug target in astrocytomas
Authors: Jing Ni, Shaozhen Xie, Shakti H. Ramkissoon, Victor Luu, Yu Sun, Pratiti Bandopadhayay, Rameen Beroukhim, Thomas M. Roberts, Charles D. Stiles, Rosalind A. Segal, Keith L. Ligon, William C. Hahn, Jean J. Zhao
Journal: Neuro-Oncology (2016)

Abstract Background. Astrocytomas are the most common primary human brain tumors. Receptor tyrosine kinases (RTKs), including tyrosine receptor kinase B (TrkB, also known as tropomyosin-related kinase B; encoded by neurotrophic tyrosine kinase receptor type 2 [NTRK2]), are frequently mutated by rearrangement/fusion in high-grade and low-grade astrocytomas. We found that activated TrkB can contribute to the development of astrocytoma and might serve as a therapeutic target in this tumor type. Methods. To identify RTKs capable of inducing astrocytoma formation, a library of human tyrosine kinases was screened for the ability to transform murine Ink4a−/−/Arf−/− astrocytes. Orthotopic allograft studies were conducted to evaluate the effects of RTKs on the development of astrocytoma. Since TrkB was identified as a driver of astrocytoma formation, the effect of the Trk inhibitors AZD1480 and RXDX-101 was assessed in astrocytoma cells expressing activated TrkB. RNA sequencing, real-time PCR, western blotting, and enzyme-linked immunosorbent assays were conducted to characterize NTRK2 in astrocytomas. Results. Activated TrkB cooperated with Ink4a/Arf loss to induce the formation of astrocytomas through a mechanism mediated by activation of signal transducer and activator of transcription 3 (STAT3). TrkB activation positively correlated with Ccl2 expression. TrkB-induced astrocytomas remained dependent on TrkB signaling for survival, highlighting a role of NTRK2 as an addictive oncogene. Furthermore, the QKI-NTRK2 fusion associated with human astrocytoma transformed Ink4a−/−/Arf−/− astrocytes, and this process was also mediated via STAT3 signaling. Conclusions. Our findings provide evidence that constitutively activated NTRK2 alleles, notably the human tumor-associated QKI-NTRK2 fusion, can cooperate with Ink4a/Arf loss to drive astrocytoma formation. Therefore, we propose NTRK2 as a potential therapeutic target in the subset of astrocytoma patients defined by QKI-NTRK2 fusion.